ESMO 2024 Insights: Dr. Jie Chen on CABINET and CVM-005 Trials in NETs

ESMO 2024 Insights: Dr. Jie Chen on CABINET and CVM-005 Trials in NETs

The 2024 European Society for Medical Oncology (ESMO) Annual Meeting has successfully concluded. Several studies presented during the neuroendocrine tumor (NET) oral sessions have offered new treatment strategies and molecular profiling for advanced unresectable NETs. Notably, the Phase III CABINET study on cabozantinib achieved its primary endpoint of progression-free survival (PFS), and the multi-center single-arm CVM-005 study showed impressive PFS results with the anti-vasculogenic mimicry drug CVM-1118, especially when combined with SSA (somatostatin analogs), with the median PFS for extra-pulmonary NETs reaching nearly two years. Furthermore, multi-omics profiling has provided a foundation for prognostic assessment, classification-based treatment, and biomarker exploration in NETs. Oncology Frontier invited Dr. Jie Chen from Fudan University Shanghai Cancer Center to introduce and comment on these studies.
Liver Cancer Breakthrough Unveiled at ESMO 2024!

Liver Cancer Breakthrough Unveiled at ESMO 2024!

Thrilled to share our interview with Professor Guohong Han about the LEAP-012 study, which could revolutionize liver cancer treatment! Combining TACE with lenvatinib and pembrolizumab is showing incredible results for intermediate-stage liver cancer: 46.8% tumor response rate Progression-free survival boosted from 10 to 14.6 months
Exclusive Insights on mHSPC Treatment: Interview with Dr. Fred Saad

Exclusive Insights on mHSPC Treatment: Interview with Dr. Fred Saad

In a recent Media Medic interview, our colleague El Bachir MOURABIT had the privilege to speak with Dr. Fred Saad about breakthrough advancements in metastatic hormone-sensitive prostate cancer (mHSPC) treatment. Dr. Saad emphasized the importance of combining androgen deprivation therapy (ADT) with ARPIs like apalutamide, enzalutamide, or abiraterone for improved survival. He also shared promising results from the Phase 3 ARINOTE study, showcasing darolutamide with ADT as a safe and effective option, especially for patients who may not tolerate chemotherapy.
Dr. Shahrukh Hashmi: Opening Pandora’s Box, Challenges in Long-Term Monitoring After CAR-T Therapy

Dr. Shahrukh Hashmi: Opening Pandora’s Box, Challenges in Long-Term Monitoring After CAR-T Therapy

As a shining new star in the medical field, CAR-T cell therapy, while significantly effective, is filled with unknowns much like Pandora's Box. From successful treatment to long-term monitoring, every step requires meticulous planning. Recently, at the 12th Lu Daopei Hematology Academic Forum, Hematology Frontier had the honor of inviting Dr. Shahrukh Hashmi from the Mayo Clinic Comprehensive Cancer Center to share in-depth insights on the optimization and practical experience of long-term monitoring strategies following CAR-T therapy.
SOHO 2024 | Dr. Valeria Santini: Imetelstat Demonstrates Durable Efficacy in the Treatment of LR-MDS

SOHO 2024 | Dr. Valeria Santini: Imetelstat Demonstrates Durable Efficacy in the Treatment of LR-MDS

Low-risk myelodysplastic syndromes (LR-MDS) are complex blood disorders characterized by the abnormal proliferation and dysfunction of marrow cells, leading to increased risks of anemia, bleeding, and infection. Although the progression of LR-MDS is relatively slow, the treatment of this disease still faces significant challenges. Existing therapeutic options, such as erythropoiesis-stimulating agents (ESAs) and immunomodulators, may alleviate symptoms to some extent but often struggle to achieve long-term disease control and can be associated with significant side effects. Against this backdrop, Dr. Valeria Santini explored the potential of Imetelstat, a first-in-class oligonucleotide telomerase inhibitor, in treating patients with LR-MDS through the IMerge trial. The 12th Annual Meeting of the Society for Hematologic Oncology (SOHO 2024) took place in Houston, USA, from September 4 to 7, 2024, bringing together top experts in the field of hematologic oncology worldwide to share the latest research findings and discuss new treatment strategies. Hematology Frontier specially invited Dr. Valeria Santini from the University of Florence, MDS Unit, Hematology, DMSC, AOUC, Florence, Italy, to delve into the research outcomes of this Phase III clinical trial, discussing the significant progress achieved by Imetelstat in improving the precision and effectiveness of LR-MDS patient treatment, and how this discovery may provide a new direction for future strategies in the MDS treatment field.
Shaping the Future of Lung Cancer Care: Dr. Caicun Zhou on IASLC’s 50th Anniversary and the Promise of HARMONi2

Shaping the Future of Lung Cancer Care: Dr. Caicun Zhou on IASLC’s 50th Anniversary and the Promise of HARMONi2

The International Association for the Study of Lung Cancer (IASLC), founded in 1974, has grown into a global organization with over 10,000 members from more than 100 countries and regions. In 2023, Dr. Caicun Zhou from Shanghai Pulmonary Hospital, Tongji University School of Medicine was elected as the IASLC President-Elect for 2023-2025 and will serve as IASLC President for 2025-2027. He is the first IASLC President from mainland China in the organization’s 50-year history. This year marks the 50th anniversary of IASLC, and at the 2024 World Conference on Lung Cancer (WCLC), Oncology Frontier had the opportunity to speak with Dr. Caicun Zhou about IASLC’s remarkable journey over the past five decades in leading the fight against thoracic cancers.
From Curious Learner to Pioneer: Dr. Jie Chen’s Medical Evolution

From Curious Learner to Pioneer: Dr. Jie Chen’s Medical Evolution

As we step further into the 21st century, the field of medicine has undergone tremendous changes. Among the many advancements, a generation of compassionate and skilled doctors has emerged, dedicated to the wellbeing of their patients and their nation. The phrase "a doctor's heart is like a parent's" perfectly captures this essence. In the Oncology Frontier series "In Conversation," we reflect on the past with renowned doctors, exploring the highs and lows of their medical journeys. In this edition, we are honored to have Dr. Jie Chen from Fudan University Shanghai Cancer Center share her story. Over the past 30 years, she has remained dedicated to her mission. With five major career transitions, she has continually embraced challenges, breaking new ground where none existed. In the virtually untouched field of neuroendocrine tumors (NEN) in China, she laid the foundation for the discipline and paved the way for future advancements.